SPX4,026.12-1.14 -0.03%
DIA343.52+1.57 0.46%
IXIC11,226.36-58.96 -0.52%

Citigroup Maintains Neutral on Clover Health Investments, Lowers Price Target to $1.8

Benzinga · 11/16/2022 07:51
Citigroup analyst Jason Cassorla maintains Clover Health Investments (NASDAQ:CLOV) with a Neutral and lowers the price target from $3.5 to $1.8.